Standard Glass Lining Technology Ltd. IPO: A Detailed Look

Standard Glass Lining Technology Ltd. will be the first mainboard Initial Public Offering (IPO) of 2025. We have outlined some key details about the IPO.

Launch and Subscription Dates

The highly anticipated initial public offering (IPO) of Standard Glass Lining Technology Ltd. is scheduled to open for subscription from January 6 to January 8, 2025, making it the first mainboard IPO of the year.

Pre-IPO Funding and Investors

Before the IPO launch, the company successfully raised Rs 123.02 crore from esteemed anchor investors. Among the notable names are Amansa Holdings, Clarus Capital, ICICI Prudential Mutual Fund, Kotak Mahindra Trustee, Tata Mutual Fund, and the Massachusetts Institute of Technology.

IPO Pricing and Details

  • Price Range: Rs 133-140 per share

  • Total Size: Rs 410.05 crore

  • Investment Lot: 107 shares per bid

The offering comprises a fresh issue amounting to Rs 210 crore and an offer for sale (OFS) of approximately 1.42 crore shares, which has been scaled down from the initially planned 1.84 crore shares.

Allocation and Premium

  • Allocation Breakdown:

    • 50% reserved for qualified institutional buyers

    • 15% for non-institutional investors

    • 35% for retail investors

The shares have a grey market premium (GMP) of Rs 88, indicating a 63% premium over the upper price band.

Use of Proceeds

The funds raised from the fresh issue will be allocated as follows:

  • Rs 130 crore for debt repayment

  • Rs 30 crore for investments in the wholly-owned subsidiary, S2 Engineering Industry

  • Rs 20 crore for strategic acquisitions

  • Rs 10 crore for new machinery and equipment

The remaining funds will be used for general corporate purposes.

Company Profile and Clients

Standard Glass Lining Technology Ltd. is renowned for its turnkey solutions catering to pharmaceutical and chemical manufacturers. Their comprehensive services include design, engineering, production, and installation. The company boasts an impressive client roster featuring top pharmaceutical players such as Aurobindo Pharma, Cadila Pharmaceuticals, Granules India, Macleods Pharmaceuticals, Piramal Pharma, and Suven Pharmaceuticals.

IPO Management and Listing

IIFL Securities and Motilal Oswal Investment Advisors are the lead managers for the IPO, with Kfin Technologies appointed as the registrar.

The share allotment is anticipated to be finalized on January 9, with a tentative listing date on the NSE and BSE set for January 13, 2025.

No comments:

Powered by Blogger.